tapebrief
DHR · Q3 2025
DHR · Q1 2026

DHR · Q4 2025 Earnings

Cautious

Danaher Corporation

Reported January 28, 2026

30-second summary

30-second take: Q4 revenue of $6.84B (+4.5% YoY, +2.5% core) and non-GAAP EPS of $2.23 closed FY2025 at the high end of the $7.70–$7.80 EPS guide ($7.80 delivered), and management initiated FY2026 at $8.35–$8.50 non-GAAP EPS on 3–6% core revenue growth — broadly in line with the framework laid out in October. The substance is what didn't change: equipment grew in Q4 for the first time in the cycle, but management held the FY2026 equipment assumption flat anyway, explicitly invoking the same "one quarter doesn't make a trend" discipline they applied to consumables six quarters ago. The FY2026 build is bioprocessing high-single-digit, equipment flat, life sciences flat, diagnostics low-single-digit — the same composition as October, with one notable change: Cepheid respiratory was raised to ~$1.8B for FY2026 (vs. the ~$1.7B previewed in October), following Q4 respiratory of ~$500M. $250M of 2025 cost actions ($0.30 EPS) does the heavy lifting on ~100bps of margin expansion.

Headline numbers

EPS

Q4 FY2025

$2.23

Revenue

Q4 FY2025

$6.84B

+4.5% YoY

Gross margin

Q4 FY2025

58.0%

Free cash flow

Q4 FY2025

$1.77B

Operating margin

Q4 FY2025

22.0%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$6.84B+4.5%$6.10B+12.1%
EPS$2.23—$1.89+18.0%
Gross margin58.0%—58.2%-23bps
Operating margin22.0%—19.1%+290bps
Free cash flow$1.77B—$1.37B+29.1%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Core revenue growth (non-GAAP)Q4 FY2025low-single digit4.5%+0.5-3.5pts above low-single digit rangeBeat
Adjusted operating profit margin (non-GAAP)Q4 FY2025approximately 27%22%-5pts below guideBeat
EPS (non-GAAP)FY2025$7.70 to $7.80$7.8at high end of prior rangeBeat
revenue growth (non-GAAP core)FY2025low-single digits year-over-year3%in-line with low-single digit rangeMet

New guidance

MetricPeriodGuideYoY
Core revenue growth (non-GAAP)Q1 FY2026low-single digit percent range year-over-year—
Adjusted operating profit margin (non-GAAP)Q1 FY2026~28.5%—
EPS (non-GAAP)FY2026$8.35 to $8.50—
core revenue growth (non-GAAP)FY20263% to 6% year-over-year—
Currency exchange rate impact on salesQ1 FY2026~+3.5%—
Currency exchange rate impact on salesFY2026~+1.0%—
Corporate expenseFY2026~$(360) million—
Interest expense, netFY2026~$(180) million—
Effective tax rateFY2026~17.0%—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Biotechnology$2.033B+9.0%
Life Sciences$2.085B+2.5%
Diagnostics$2.72B+3.0%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Biotechnology Operating Margin26.6%
Life Sciences Operating Margin16.1%
Diagnostics Operating Margin26.2%
Cepheid Respiratory Revenue (Q4)~$500M
Operating Cash Flow Conversion (Q4)1.79x
Free Cash Flow Conversion (Q4)1.50x

Management tone

Q1 → Q2 → Q3 → Q4: equipment normalization expected → "more complex" macro → workable policy with no order conversion → first quarter of equipment growth, but still guide flat.

Equipment language has now travelled the full arc from "uncertainty" to "encouraging but early" — and management is deliberately not crediting it. Three quarters ago equipment was the source of macro overhang; last quarter the language was "workable, not ideal"; this quarter equipment grew mid-single-digits in Q4 for the first time, with three consecutive quarters of sequential order growth. From the Wolfe Q&A: management compared the situation to consumables "six or eight quarters ago when early signs emerged" and explicitly said "one quarter does not make a trend." The flat FY2026 equipment assumption is being held as a discipline call, not a forecast — the same playbook used on consumables before that recovery materialized. This is the cleanest articulation yet of management's preference to underwrite guidance to actuals rather than to leading indicators.

Pharma end markets have improved for three consecutive quarters — a streak that didn't exist a year ago. Last quarter the recovery framing degraded from "footing" to "modest." This quarter management was specific: pharma improved for a third consecutive quarter, CyEx grew mid-single digits with a new product (ZenoTOF 8600) contributing, and clinical/applied markets are stable. Academic/government remains muted with potential choppiness but is expected to moderate. The shift signals the life sciences flat assumption embedded in the 3–6% range is now genuinely conservative on the downside, not a fragile baseline.

M&A posture moved from absent to active in the dialogue. Last quarter M&A barely surfaced. This quarter Wolfe asked directly and management said the environment is "more constructive with valuations and rates moving favorably," the balance sheet is "primed" (debt-to-EBITDA below 2x), and discipline on end-market tailwinds and defensible assets is intact. No targets disclosed. With organic growth modeled at 3–6% and an EPS bridge that already uses up the easy cost-action lever, M&A is being teed up as the next leg of the framing — the first time in four quarters that's been explicitly the case.

Margin guidance is being undersized again, on the same logic. The CFO last quarter said error bars on >100bps skew upside; this quarter the FY2026 guide implies ~100bps margin expansion delivered by $0.30 of cost-action EPS (~50bps) plus 35–40% fall-through on volume. The Q1 ~28.5% adj. operating margin starting point is consistent with the framing that H2 carries more of the year as cost actions flow through. The deliberate undersizing pattern is now three quarters old and worth pricing into expectations.

Q&A highlights

Michael Riskin · Bank of America

How much conservatism is embedded in the 3-6% core revenue guidance, and what are the key levers or drivers that could drive performance toward the high end of the range?

Management indicated the guidance is based on continued end market recovery. Bioprocessing expected to remain strong in high single digits; life sciences expected to be flat with modest improvements; diagnostics expected to grow in low single digits. Two main upside levers: (1) continued improvement in life science end markets, particularly biotech funding and China recovery; (2) bioprocessing accelerating beyond high single digits if biosimilar and mAb production increases.

3-6% core revenue guidance for 2026Bioprocessing: high single-digit growth expectedEquipment: assumed flat for 2026 (off mid-teens decline in 2025)Life sciences discovery and medical: expected flat

Tycho Peterson · Jefferies

What is driving CyEx strength (new product innovation vs. end market recovery), and how should investors think about margin flow-through and full-year margin progression for 2026?

CyEx mid-single-digit growth driven by multiple factors: new product (Xenotop 8600), continued pharma end market improvement (third consecutive quarter), robust clinical/applied markets, and stable (but not growing) academic/government. On margins: first quarter OPM ~28.5%; expect incremental margins to follow core growth trajectory with easiest comps in life science consumables and China DX in H2. Cost savings benefits concentrated in Q4 2025 and flowing through H2 2026.

CyEx grew mid-single digits in Q4Pharma end market grew for third consecutive quarterFirst quarter adjusted OPM guidance: ~28.5%Low single-digit core growth expected early in year, accelerating through 2026

Doug Schenkel · Wolfe Research

Why didn't management guide for stronger bioprocessing equipment growth given Q4 strength and favorable 2026 comparisons, and is there prudence baked in? Also, what is management's appetite for M&A given improved balance sheet and more constructive environment?

Management acknowledged Q4 equipment growth was encouraging but only one quarter; cautious approach similar to consumables 6-8 quarters ago when early signs emerged. One quarter does not make a trend; guiding flat is prudent given uncertain macro environment. On M&A: environment more constructive with valuations and rates moving favorably. Management maintaining disciplined approach focused on attractive end markets, defensible assets, and sound financial models. Balance sheet is 'primed' for action.

Equipment grew single digits in Q4 (first quarter of growth)Equipment backlog and orders from past three quarters encouraging but early2026 equipment guidance: flatDebt-to-EBITDA: below 2x

Jack Meehan · Nephron Research

Were there push-outs from earlier in 2025 that came in at year-end in life sciences, and could Q4 represent an elevated base? Also, what are the specific margin puts and takes for 2026 EPS guidance?

Some budget flush in Europe in Q4, but not enormous; not a reliable read-through. Pharma end market improving for three consecutive quarters; clinical/applied stable; academic/government muted with potential choppiness ahead but expected to moderate. On margins: EPS guidance $8.35-$8.50 assumes 3-4% core growth at low end, 35-40% fall-through, 30-cent benefit from 2025 cost actions (50 bps of the ~100 bps margin expansion), and neutral FX assumption.

Some budget flush observed in Europe in Q4Pharma improved three consecutive quartersEPS guidance range: $8.35-$8.50Assumed core growth: 3-4% (low end of range)

Dan Lerner · UBS

How sensitive is the biotech business segment to improvements in biotech funding, and what is the current trajectory of reshoring conversations with customers?

Biotech sector represents ~15% of discovery and medical business, ~5% of overall Danaher, and 10-15% of bioprocessing. Not majority of business; most bioprocessing driven by commercial volume (75%), with 25% mix of clinical and biotech. Some improved orders from biotech in bioprocessing but early days. On reshoring: ongoing conversations indicate long-term investment cycle beginning; timing difficult to pinpoint but catch-up required to meet demand. Danaher well-positioned; encouraged by order book for equipment.

Biotech: 15% of discovery and medical, 5% of total Danaher, 10-15% of bioprocessingCommercial volume: 75% of bioprocessingClinical and biotech: remaining 25% of bioprocessingImproved biotech orders emerging but early

Answers to last quarter's watch list

Equipment order conversion — Equipment grew mid-single-digits in Q4, the first quarter of growth in the cycle, with backlog and three consecutive quarters of sequential order growth. Management explicitly chose not to credit this in FY2026 (still guiding equipment flat off the mid-teens 2025 decline), comparing it to consumables six to eight quarters before that recovery materialized. The data turned positive; the guide didn't.
Resolved positively
Life sciences consumables stabilization at the two named large customers — Not specifically called out this quarter. Management did note pharma end markets improved for the third consecutive quarter and life sciences is assumed flat in FY2026. The specific plasmid/mRNA two-customer drag from Q3 wasn't re-quantified.
Continue monitoring
FY2025 EPS landing within or above $7.70–$7.80 — Delivered $7.80, the high end of the range. Q4 non-GAAP EPS of $2.23 confirmed the back-half-loaded shape held. The FY2026 starting point is firmer as a result.
Resolved positively
Cepheid respiratory tracking toward the FY2026 endemic rate — Q4 respiratory came in at ~$500M, exceeding expectations on active respiratory season demand. Management raised the FY2026 endemic assumption to ~$1.8B (from ~$1.7B in the October preview) after revisiting typical-year patterns with the team. Status: Resolved (raised)
China VBP headwind sizing for 2026 — Not specifically re-quantified this quarter. Management referenced easier China Diagnostics comps as a H2 2026 tailwind and said VBP headwinds "will moderate as we move through the year" but didn't update the prior sizing.
Not resolved
Margin upside vs. >100bps 2026 commitment — FY2026 EPS guide of $8.35–$8.50 implies ~7–9% EPS growth on 3–6% revenue growth, consistent with the ~100bps commitment. The CFO's "error bars skew upside" framing didn't translate into an early raise; the guide was set at the level previewed in October. Status: Resolved (held, no raise)

What to watch into next quarter

Equipment guide revision — management is explicitly running the consumables-recovery playbook on equipment, treating Q4 as one data point. A second consecutive quarter of equipment growth on the April call materially shifts the FY2026 setup toward the high end of 3–6%; absence of follow-through validates the flat assumption.

Q1 actual operating margin vs ~28.5% guide — the year is back-half-loaded by design; a Q1 OPM print that meets or beats 28.5% removes risk on the full-year ~100bps expansion and the $8.35–$8.50 EPS range.

M&A activity — balance sheet "primed" with debt-to-EBITDA below 2x and management framing the environment as more constructive; watch for a transaction announcement or any escalation of language. M&A is now the only undisclosed leg of the FY2026 framing.

Cepheid respiratory tracking through Q1 — Q1 respiratory is guided to ~$500M; Q1 is the high seasonal quarter and the first real test of the newly raised ~$1.8B FY2026 endemic baseline. A meaningful gap reopens the diagnostic mix question.

Biotech end-market orders — management said improved biotech orders are emerging in bioprocessing "but early." Conversion into a sustained order trend through Q1 supports bioprocessing accelerating beyond high-single-digit and pushes FY2026 toward 5–6%.

Pharma end-market streak — three consecutive quarters of improvement; a fourth confirms life sciences flat is a conservative baseline and increases upside optionality on the FY2026 range.

Sources

  1. Danaher Q4 FY2025 Press Release (SEC EDGAR), 2026-01-28: https://www.sec.gov/Archives/edgar/data/313616/000031361626000004/dhr-20260128xex991.htm
  2. Danaher Q4 FY2025 earnings call — prepared remarks and Q&A

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.